PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Revenue of PainReform Ltd. (PRFX)
Revenue in 2023 (TTM): $
According to PainReform Ltd.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PainReform Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-15,000 | $-9,569,000 | $-9,336,000 | $-9,344,000 |
| 2022 | $86 K | $71 K | $-8,707,000 | $-8,783,000 | $-8,792,000 |
| 2021 | $ | $-7,000 | $-7,211,000 | $-7,240,000 | $-7,246,000 |
| 2020 | $ | $ | $-1,739,000 | $-3,833,000 | $-4,053,000 |
| 2019 | $ | $-1,000 | $-737,000 | $-1,279,000 | $-1,820,000 |
| 2018 | $ | $ | $-501,000 | $-828,000 | $-828,000 |
| 2017 | $ | $ | $-1,210,000 | $-1,122,000 | $-2,090,000 |